Febuxostat Vs Allopurinol untuk Penatalaksanaan Hiperurisemia

Oleh :

dr.Eduward Thendiono, SpPD,Finasim,IDF-Fellow

Agen terapi hiperurisemia yang paling sering digunakan saat ini adalah obat golongan inhibitor xantin oksidase (XOI), yaitu allopurinol dan febuxostat. Kedua obat ini memiliki profil efikasi dan keamanan berbeda, seperti pada populasi dengan komorbiditas kardiovaskular dan gangguan ginjal. Meski demikian, apakah febuxostat atau allopurinol lebih unggul dari satu sama lain masih menjadi kontroversi.[1-3]

Hiperurisemia adalah peningkatan kadar asam urat serum >6,8 mg/dL (≥0,4 mmol/L). Kondisi ini dapat menyebabkan penyakit gout, batu saluran kemih, insufisiensi ginjal, bahkan penyakit kardiovaskuler.[1-3]

Pedoman dari American College of Rheumatology (ACR) maupun European League Against Rheumatism (EULAR) merekomendasikan penurunan serum asam urat di bawah 6 mg/dL (0,36 mmol/L), bahkan lebih rendah hingga <5 mg/dL (<0,3 mmol/L) pada pasien dengan deposit kristal asam urat.[1,4,5]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Cutolo M, Cimmino MA, Perez-Ruiz F. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs allopurinol. Eur Rev Med Pharmacol Sci.2017;21:4186-4195.
2. Borghi C et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015;33:1729-1741. doi: 10.1097/HJH.0000000000000701.
3. Mancia G, Grassi G, Broghi C. Hyperuricemia, urate deposition and the association with hypertension. Curr Med Res Opin 2015: 31: 15-19. doi: 10.1185/03007995.2015.1087981.
4. Richete P et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42. doi: 10.1136/annrheumdis-2016-209707.
5. Khanna D et al. American College of Rheumatology 2012 Guidelines for Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arhtritis Care Res (Hoboken) 2012; 64: 1431-1446. doi: 10.1002/acr.21772
6. Gerriets V, Jialal I. Febuxostat. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK544239/
7. Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum. 2013;43(3):367-375. doi:10.1016/j.semarthrit.2013.05.004
8. Li, S., Yang, H., Guo, Y. et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Sci Rep 6, 33082 (2016). https://doi.org/10.1038/srep33082
9. Mackenzie IS et al. FASR Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, ope label, non-inferiority trial. Lancet.2020;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0.
10. Gao, L, Wang, B, Pan, Y, Lu, Y, Cheng, R. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis. Clin Cardiol. 2021; 44( 7): 907– 916.https://doi.org/10.1002/clc.23643
11. Rey, A., Batteux, B., Laville, S.M. et al. Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study. Arthritis Res Ther 21, 229 (2019). https://doi.org/10.1186/s13075-019-2011-y
12. Yang AY. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases. Int J Clin Pharmacol Ther. 2020;58(1):21-28. doi:10.5414/CP203466
13. Peng, YL., Tain, YL., Lee, CT. et al. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Sci Rep 10, 10734 (2020). https://doi.org/10.1038/s41598-020-67026-1
14. Xie H, Hu N, Pan T, Wu JC, Yu M, Wang DC. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2023; 24(1):79. doi: 10.1186/s40360-023-00723-5.